Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
Science Translational Medicine.
Times cited: 688
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.
Times cited: 592
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.
Journal of Immunotherapy.
Times cited: 111